Catalent Completes Expansion of Its Advanced Dose Form Facility In Italy

Catalent Completes Expansion of Its Advanced Dose Form Facility In Italy

Somerset, NJ - February 1, 2012 - Catalent Pharma Solutions announces the completion of the on-going expansion of its facility in Aprilia, Italy. This expansion offers customers a complete ‘turnkey' service from product conceptualization to formulation, development, production and packaging for prescription and over-the-counter products. It also further enhances Catalent's comprehensive European quality and analytical capabilities that include a wide range of services such as market registration, analytical testing and market release by Qualified Persons.

Catalent has proven expertise in overcoming solubility, stability and bioavailability challenges for a wide range of liquid and semi-solid formulations. Innovative products manufactured at its Aprilia site include Vegicaps® capsules which enable better treatments through enhanced bioavailability for a wide range of APIs requiring higher temperature processing.

"Expanding our drug delivery capabilities and expertise reinforces Catalent Aprilia's position as a leading integrated development and delivery facility in Southern Europe," said Stefano Arena, General Manager of the site.

This expansion was successfully inspected by the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA) last month, and is the latest in a number of expansions that Catalent has made across Europe, South America and the United States.
About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue.

 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.